Bouffet Eric, Capra Michael, Bartels Ute
Paediatric Neuro-Oncology Program, The Hospital for Sick Children, 555 University Avenue, Toronto, M5G1X8, Canada.
Childs Nerv Syst. 2009 Oct;25(10):1293-301. doi: 10.1007/s00381-009-0883-x. Epub 2009 Apr 10.
Chemotherapy has limited role in the up-front management of ependymoma. At the time of recurrence, the role of chemotherapy is also ill defined and the choice of chemotherapeutic agents is often arbitrary, based on anecdotal data and personal experience.
The purpose of this review is to describe and critically analyze the published literature on chemotherapy in patients with recurrent and metastatic ependymoma.
The disappointing response rate with single agents (12.9%) and combinations (17.4%) emphasizes the need to re-evaluate the current chemotherapeutic approach of intracranial ependymoma, and biological studies are needed to identify targets that may be considered for clinical trials.
化疗在室管膜瘤的初始治疗中作用有限。在复发时，化疗的作用也不明确，化疗药物的选择往往基于轶事性数据和个人经验，具有随意性。
本综述的目的是描述并批判性分析已发表的关于复发性和转移性室管膜瘤患者化疗的文献。
单药（12.9%）和联合用药（17.4%）令人失望的缓解率强调了重新评估当前颅内室管膜瘤化疗方法的必要性，并且需要开展生物学研究以确定可考虑用于临床试验的靶点。
